US/UK/Canada

Share

Contacts

  • Brede Ellingsæter

    Chief Financial Officer


    Karenlyst Alle 9C, 0278 Oslo, Norway
    +47 47238440
    +47 47238440
    http://www.thormedical.no
    • Pick a time period -
    Tags ( Active)

    Nordic Nanovector ASA announces that Ludvik Sandnes has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO)

    Oslo, Norway, 31 January 2023 Nordic Nanovector ASA (“Nordic Nanovector” or the “Company”) announces that Ludvik Sandnes, former Chairperson of Nordic Nanovector, has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of the Company as from 1 February 2023. Ludvik Sandnes will no more attend the Oncoinvent Board. Malene Brondberg, current interim CEO and CFO, will transition out of the Company, as previously announced on 9 December 2022. Ludvik Sandnes commented “I have been asked by the board of Nordic Nanovector to become the interim CEO and CFO

    Nordic Nanovector ASA Notes Publication of Letter by Largest Shareholder North Energy

    Oslo, Norway, 16 January 2023 Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") notes the publication of a letter on 10 January 2023 by North Energy ASA, the largest shareholder of the Company holding approximately 16.5% of the outstanding votes and shares in the Company. In the letter, North Energy requests additional financial information to be published to all shareholders in the upcoming Q4 report due on 28 February 2023; and secondly that the Company pre-announce certain key preliminary financial information prior to the Q4 report (no later than 16 January 2023).

    Nordic Nanovector ASA: Extraordinary General Meeting held

    Oslo, Norway, 3 January 2023 An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 3 January 2023 in Oslo, Norway. A new Board of Directors consisting of Jon Magne Asmyr (chairperson), Eddie Berglund and Tina Bjørnlund Bønsdorff was elected by the EGM, as well as a new Nomination Committee consisting of Hans Peter Bøhn (chairperson), Jan-Tore Pedersen and Vegard Aavik. The complete minutes of the EGM are attached to this release, and are available on www.nordicnanovector.com. For further information, please contact:

    Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023

    Oslo, Norway, 13 December 2022 Nordic Nanovector ASA's ("Nordic Nanovector" or the "Company") largest shareholder North Energy ASA, that now holds 11,518,448 shares in the Company, has requested that the Board of Directors calls for an Extraordinary General Meeting in accordance with the Norwegian Public Limited Liability Companies Act §5-7 (2). The Board of Directors therefore calls for an Extraordinary General Meeting to be held on 3 January 2023, at 16:00 hours CET at Advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo. The full notice with appendices is attached. The notice and

    Nordic Nanovector update following shareholder vote against proposed merger with APIM Therapeutics

    Oslo, Norway, 9 December 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces an update following the Extraordinary General Meeting held on 1 December at which the proposed merger transaction with APIM Therapeutics AS (“APIM”) did not obtain a sufficient majority of votes and was therefore voted down. A new Extraordinary General Meeting ("EGM") will be convened by the Board of Directors with an agenda proposed by North Energy. North Energy is currently the largest shareholder of Nordic Nanovector. The current Board of Directors of Nordic

    Nordic Nanovector ASA: Extraordinary General Meeting held

    Oslo, Norway, 1 December 2022 An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 1 December 2022 in Oslo, Norway. The matters under item 3, the proposed transaction with APIM Therapeutics AS, did not obtain sufficient majority of votes and was thus voted down. Due to the results under item 3, the EGM did not vote for the matters under item 4, 5, 6 and 7. The complete minutes of the EGM are attached to this release, and are available on www.nordicnanovector.com. For further information, please contact: IR enquiries

    Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics

    Oslo, Norway, 25 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website (www.nordicnanovector.com) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics (“APIM”). The new area includes a recording of the webcast and Question & Answer session, which was held for interested parties, including shareholders, on 24 November. During the webcast, shareholders were provided with a more-detailed presentation of the proposed merger with APIM and were given the

    Nordic Nanovector: Invitation to webcast regarding proposed merger with APIM Therapeutics

    Oslo, Norway, 23 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") will host a webcast, including a question and answers session on Thursday, November 24 at 4.30 P.M. CET. Reference is made to the stock exchange announcement regarding the Company comments on the proposed merger with APIM Therapeutics November 21. A webcast will be held as described below: Participation details In order to listen to the presentation, visit the Company’s website www.nordicnanovector.com and click on the link to “Webcast”, or sign up and access directly via the

    Nordic Nanovector comment on Proposed Merger with APIM Therapeutics

    Oslo, Norway, 21 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") desires to share more information with the Company’s shareholders about the proposed merger between the Company and APIM Therapeutics (“APIM”). The Company has scheduled a webcast, including a question and answers session, on Thursday, November 24 at 4.30 CET. Practical details regarding the webcast will be issued in a separate notice. Any questions may be submitted to ir@nordicnanovector.com. The Board of Nordic Nanovector and its advisors reiterates its belief that the merger

    Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 1 December 2022

    Oslo, Norway, 10 November 2022 Reference is made to the stock exchange announcement by Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") on 9 November 2022 announcing that the Company has entered into a merger agreement with all shareholders of APIM Therapeutics AS to combine the companies in an all-stock transaction. Completion of the transaction is dependent on the approval by the General Meeting of the Company. Nordic Nanovector hereby calls for an Extraordinary General Meeting in the Company to be held on 1 December 2022, at 10:00 hours CET at Advokatfirmaet Selmer,

    Nordic Nanovector and APIM Therapeutics Announce Merger Agreement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. · Merger to create a clinical-stage biotechnology company focused on advancing a portfolio of oncology programmes including a Phase 1b/2a clinical study in platinum-sensitive ovarian cancer and a Phase 2 clinical study in sarcoma · Combined company is expected to have funding into 2024 · Companies will host a joint webcast on 10 November 2022 at 10:00 a.m. CET. The

    Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting

    Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting Oslo, Norway, 3 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") announces the progress it has made in designing and developing a portfolio of novel and potent humanized anti-CD37 monoclonal antibodies with potential for treating B-cell malignancies or B-cell-driven autoimmune disorders. Details of the Company’s progress in engineering this portfolio are included in two

    Nordic Nanovector consolidates Board to conserve resources while it explores strategic options

    Oslo, Norway, 15 September 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces that following the decisions to discontinue the PARADIGME study for its lead asset Betalutin[®], restructure the company and appoint Carnegie Investment Bank to explore strategic options three members of the Company’s Board have decided to step down. Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl will step down from the Board with immediate effect. As previously announced in the press release of 18 August 2022 a strategic exercise led by Carnegie has

    Nordic Nanovector ASA Results for the Second Quarter and First Half 2022

    Oslo, Norway, 31 August 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") announces its results for the second quarter and first half 2022. A presentation by Nordic Nanovector’s senior management team will be held in-person today in Oslo and webcast live beginning at 8:30am CEST – details below. Jan H. Egberts Chairman of Nordic Nanovector, commented: “The decision to discontinue PARADIGME* has been a major disappointment for everyone involved, most particularly patients. Given the difficult financing environment and the Company’s current financial

    Nordic Nanovector consolidates senior leadership team and restructures to conserve resources as it explores strategic options

    Oslo, Norway, 26 August 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces that further to the decisions to discontinue the PARADIGME study for its lead asset Betalutin[®], restructure the company and appoint Carnegie Investment Bank to explore strategic options the senior leadership team will be consolidated, and current Chief Executive Officer Erik Skullerud will transition out of his role. Nordic Nanovector’s Chief Financial Officer Malene Brondberg will assume the combined position of CFO and interim CEO while the Company continues to

    Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2022 Results Presentation Webcast

    Oslo, Norway, 24 August 2022 Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the second quarter and first half 2022 on Wednesday, 31 August 2022. A presentation by Nordic Nanovector's senior management team will be held in-person and webcast live beginning at 8:30am CEST. Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Bjørvika The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event. The results report and the

    Nordic Nanovector to explore strategic options

    Oslo, Norway, 18 August 2022 Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) today announces that its Board of Directors (the “Board”) has appointed Carnegie Investment Bank (“Carnegie”) to explore strategic options available to the Company. The Board has initiated this review aiming to optimise shareholder value following its recent decision to discontinue the PARADIGME study for Nordic Nanovector’s lead asset Betalutin® and implement a restructuring of the Company. Chairman, Jan H. Egberts commented: “The decision to discontinue the PARADIGME study was

    Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma

    Webcast to be held at 08.30 CEST on Wednesday 6 JulyOslo, Norway, 5 July 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL). Following a comprehensive review and independent data evaluation of PARADIGME and a subsequent request for regulatory agency interaction, the Board of Directors (Board) has taken the difficult decision to discontinue the study. No further patients will be enrolled into PARADIGME. The

    Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma

    Oslo, Norway, 21 June 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update following its comprehensive review and independent data evaluation of PARADIGME, its ongoing Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL). The independent expert panel reviewed the efficacy data collected to date. Betalutin®, at the selected dose of 15 MBq/kg after a pre-dose of 40 mg lilotomab (40/15), has continued to display an attractive safety profile. While Betalutin® showed signs of

    Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting

    Oslo, Norway, 10 June 2022 Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® ([177]Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation. The latest data to be presented at the European Hematology Association (EHA) Congress in Vienna, Austria on 10 June 2022 shows that Betalutin® continues to be well tolerated with no further dose-limiting toxicity (DLT). The data analysis showed that clinical activity of Betalutin® was seen

    Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment

    Oslo, Norway, 2 June 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL). As highlighted at the recent Q1 results, reported on 13 May 2022, recruitment into PARADIGME has been slower than anticipated, and despite ongoing efforts by the company this has continued into Q2 with no additional patients enrolled in May. As a result, the Board of Nordic Nanovector has decided to conduct a comprehensive

    Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

    Oslo, Norway, 20 May 2022 Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANOV) annual general meeting held on 28 April 2022 in Oslo, Norway (the "AGM"). At the AGM, the shareholders approved the issuance of restricted stock units ("RSUs") to board members who elect to receive all or parts of their remuneration, for the period from the annual general meeting in 2022 to the annual general meeting in 2023, in the form of RSUs.   The RSUs are non-transferable and each RSU give the right and obligation to acquire one share in the Company at a price

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe